BIOMAT Database Logo BIOMAT Database Logo

Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine. 2018

Huong Q McLean, and Herve Caspard, and Marie R Griffin, and Manjusha Gaglani, and Timothy R Peters, and Katherine A Poehling, and Christopher S Ambrose, and Edward A Belongia
Marshfield Clinic Research Institute, Marshfield, Wisconsin.

Some studies have reported negative effects of prior-season influenza vaccination. Prior-season influenza vaccination effects on vaccine effectiveness (VE) in children are not well understood. To assess the association of prior-season influenza vaccination with subsequent VE in children aged 2 to 17 years. This multiseason, test-negative case-control study was conducted in outpatient clinics at 4 US sites among children aged 2 to 17 years with a medically attended febrile acute respiratory illness. Participants were recruited during the 2013-2014, 2014-2015, and 2015-2016 seasons when influenza circulated locally. Cases were children with influenza confirmed by reverse-transcription polymerase chain reaction. Test-negative control individuals were children with negative test results for influenza. Vaccination history, including influenza vaccine type received in the enrollment season (live attenuated influenza vaccine [LAIV], inactivated influenza vaccine [IIV], or no vaccine) and season before enrollment (LAIV, IIV, or no vaccine), determined from medical records and immunization registries. LAIV and IIV effectiveness by influenza type and subtype (influenza A[H1N1]pdm09, influenza A[H3N2], or influenza B), estimated as 100 × (1 - odds ratio) in a logistic regression model with adjustment for potential confounders. Prior season vaccination associations were assessed with an interaction term. Of 3369 children (1749 [52%] male; median age, 6.6 years [range, 2-17 years]) included in the analysis, 772 (23%) had a positive test result for influenza and 1674 (50%) were vaccinated in the enrollment season. Among LAIV recipients, VE against influenza A(H3N2) was higher among children vaccinated in both the enrollment and 1 prior season (50.3% [95% CI, 17.0% to 70.2%]) than among those without 1 prior season vaccination (-82.4% [95% CI, -267.5% to 9.5%], interaction P < .001). The effectiveness of LAIV against influenza A(H1N1)pdm09 was not associated with prior season vaccination among those with prior season vaccination (47.5% [95% CI, 11.4% to 68.9%]) and among those without prior season vaccination (7.8% [95% CI, -101.9% to 57.9%]) (interaction P = .37). Prior season vaccination was not associated with effectiveness of IIV against influenza A(H3N2) (38.7% [95% CI, 6.8% to 59.6%] among those with prior-season vaccination and 23.2% [95% CI, -38.3% to 57.4%] among those without prior-season vaccination, interaction P = .16) or with effectiveness of IIV against influenza A[H1N1]pdm09 (72.4% [95% CI, 56.0% to 82.7%] among those with prior season vaccination and 67.5% [95% CI, 32.1% to 84.4%] among those without prior season vaccination, interaction P = .93). Residual protection from prior season vaccination only (no vaccination in the enrollment season) was observed for influenza B (LAIV: 60.0% [95% CI, 36.8% to 74.7%]; IIV: 60.0% [36.9% to 74.6%]). Similar results were observed in analyses that included repeated vaccination in 2 and 3 prior seasons. Influenza VE varied by influenza type and subtype and vaccine type, but prior-season vaccination was not associated with reduced VE. These findings support current recommendations for annual influenza vaccination of children.

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D014613 Vaccines, Attenuated Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. Attenuated Vaccine,Vaccines, Live, Attenuated,Attenuated Vaccines,Vaccine, Attenuated
D015164 Vaccines, Inactivated Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins. Inactivated Vaccine,Killed Vaccine,Killed Vaccines,Vaccines, Killed,Inactivated Vaccines,Vaccine, Inactivated,Vaccine, Killed
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Huong Q McLean, and Herve Caspard, and Marie R Griffin, and Manjusha Gaglani, and Timothy R Peters, and Katherine A Poehling, and Christopher S Ambrose, and Edward A Belongia
Live Attenuated and Inactivated Influenza Vaccine Effectiveness.
February 2019, Pediatrics,
Huong Q McLean, and Herve Caspard, and Marie R Griffin, and Manjusha Gaglani, and Timothy R Peters, and Katherine A Poehling, and Christopher S Ambrose, and Edward A Belongia
[Influenza vaccination in children: Inactivated vaccines or live attenuated vaccines?]
March 2017, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
Huong Q McLean, and Herve Caspard, and Marie R Griffin, and Manjusha Gaglani, and Timothy R Peters, and Katherine A Poehling, and Christopher S Ambrose, and Edward A Belongia
Cost Effectiveness of Influenza Vaccine for U.S. Children: Live Attenuated and Inactivated Influenza Vaccine.
September 2016, American journal of preventive medicine,
Huong Q McLean, and Herve Caspard, and Marie R Griffin, and Manjusha Gaglani, and Timothy R Peters, and Katherine A Poehling, and Christopher S Ambrose, and Edward A Belongia
Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine.
February 2016, Pediatrics,
Huong Q McLean, and Herve Caspard, and Marie R Griffin, and Manjusha Gaglani, and Timothy R Peters, and Katherine A Poehling, and Christopher S Ambrose, and Edward A Belongia
Do parents prefer inactivated or live attenuated influenza vaccine for their children?
November 2018, Vaccine,
Huong Q McLean, and Herve Caspard, and Marie R Griffin, and Manjusha Gaglani, and Timothy R Peters, and Katherine A Poehling, and Christopher S Ambrose, and Edward A Belongia
Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination.
February 2009, Vaccine,
Huong Q McLean, and Herve Caspard, and Marie R Griffin, and Manjusha Gaglani, and Timothy R Peters, and Katherine A Poehling, and Christopher S Ambrose, and Edward A Belongia
Live attenuated and inactivated influenza vaccine in school-age children.
May 1990, American journal of diseases of children (1960),
Huong Q McLean, and Herve Caspard, and Marie R Griffin, and Manjusha Gaglani, and Timothy R Peters, and Katherine A Poehling, and Christopher S Ambrose, and Edward A Belongia
Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines.
December 2006, Journal of virology,
Huong Q McLean, and Herve Caspard, and Marie R Griffin, and Manjusha Gaglani, and Timothy R Peters, and Katherine A Poehling, and Christopher S Ambrose, and Edward A Belongia
Influenza vaccination with a live attenuated vaccine.
October 2009, The American journal of nursing,
Huong Q McLean, and Herve Caspard, and Marie R Griffin, and Manjusha Gaglani, and Timothy R Peters, and Katherine A Poehling, and Christopher S Ambrose, and Edward A Belongia
Live attenuated versus inactivated influenza vaccine in infants and young children.
February 2007, The New England journal of medicine,
Copied contents to your clipboard!